DIABIO Stock Overview
Operates as a biotechnology company in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Diagonal Bio AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.033 |
| 52 Week High | SEK 0.61 |
| 52 Week Low | SEK 0.0063 |
| Beta | -2.1 |
| 11 Month Change | -4.84% |
| 3 Month Change | 33.60% |
| 1 Year Change | -89.71% |
| 33 Year Change | -99.51% |
| 5 Year Change | n/a |
| Change since IPO | -99.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| DIABIO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -12.1% | -5.8% | -2.1% |
| 1Y | -89.7% | 14.3% | 10.8% |
Return vs Industry: DIABIO underperformed the Swedish Biotechs industry which returned 17.8% over the past year.
Return vs Market: DIABIO underperformed the Swedish Market which returned 12.5% over the past year.
Price Volatility
| DIABIO volatility | |
|---|---|
| DIABIO Average Weekly Movement | 48.2% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: DIABIO's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: DIABIO's weekly volatility has increased from 34% to 48% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 4 | Karin Wehlin | diagonalbio.com |
Diagonal Bio AB (publ) operates as a biotechnology company in Sweden. The company offers LAMPlify, a customized system for general laboratory use to identify the presence of specific genetic markers for, for example, fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor’s office, surgery, mobile clinics, hospital bedsides, and workplaces and airports.
Diagonal Bio AB (publ) Fundamentals Summary
| DIABIO fundamental statistics | |
|---|---|
| Market cap | SEK 13.38m |
| Earnings (TTM) | -SEK 10.20m |
| Revenue (TTM) | SEK 1.21m |
11.1x
P/S Ratio-1.3x
P/E RatioIs DIABIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIABIO income statement (TTM) | |
|---|---|
| Revenue | SEK 1.21m |
| Cost of Revenue | -SEK 58.00k |
| Gross Profit | SEK 1.27m |
| Other Expenses | SEK 11.47m |
| Earnings | -SEK 10.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | -0.025 |
| Gross Margin | 104.79% |
| Net Profit Margin | -842.98% |
| Debt/Equity Ratio | 0% |
How did DIABIO perform over the long term?
See historical performance and comparison